

ANG003-22-101: A Phase 1, Open-Label, Multicenter Study to Assess the Safety and Efficacy of ANG003 in Patients with Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis

Status: Recruiting

Eligibility Criteria

Sex: Male or Female

Age Group: 18 years and over

This study is NOT accepting healthy volunteers

Inclusion Criteria:

- confirmed diagnosis of cystic fibrosis (CF) - clinically controlled Exocrine Pancreatic Insufficiency (EPI) with minimal symptoms - adequate nutritional status measured by body mass index of at least 20kg/m²

Exclusion Criteria:

- diagnosis of diabetes mellitus who are unable to refrain from short-acting and rapid-acting insulin on Days 1 and 5 for a daily total of 6 hours - involuntary loss of 10% or more of usual body weight within last 6 months or involuntary loss of more than 5% of body weight within 1 month - requires use of naso-gastric, J-tube, G-tube, and/or enteral feeding - CF pulmonary exacerbation within last 30 days - additional criteria (study staff will review)

Conditions & Interventions

Interventions:

Drug: ANG003

Conditions:

Rare Diseases

Keywords:

CF, Cystic Fibrosis, EPI, Exocrine Pancreatic Insufficiency

More Information

Description: This experimental drug is being studied as a possible treatment for Exocrine Pancreatic Insufficiency (EPI) caused by Cystic Fibrosis (CF). EPI is the inability to properly release pancreatic enzymes that help digest and absorb the food you eat so that your body can use it. During this study, participants will receive one dose of ANG003 with a provided test meal. Participation in this study will last approximately 30 days and will include approximately six study visits; and three telemedicine calls.

Study Contact: Brooke Noren - boer0039@umn.edu

Principal Investigator: Elissa Downs

IRB

Number: SITE00001965

Thank you for choosing StudyFinder. Please visit <http://studyfinder.umn.edu> to find a Study which is right for you and contact sfinder@umn.edu if you have questions or need assistance.